Publications by the researcher in collaboration with Sonia Eiras Penas (68)

2026

  1. Corrigendum to ‘FABP4, marker of worse prognosis in cardiovascular disease, induces neutrophil’s proatherogenic phenotype which is modulated by semaglutide’(Journal of Molecular and Cellular Cardiology, (2026), 210, C, (12-27), (S0022282825001932), 10.1016/j.yjmcc.2025.10.009)

    Journal of Molecular and Cellular Cardiology

  2. FABP4, marker of worse prognosis in cardiovascular disease, induces neutrophil's proatherogenic phenotype which is modulated by semaglutide

    Journal of Molecular and Cellular Cardiology, Vol. 210, pp. 12-27

2025

  1. Meteorin-like protein plasma levels are associated with worse outcomes in de novo heart failure

    European Journal of Clinical Investigation, Vol. 55, Núm. 4

  2. Multiparametric assessment of atrial cardiopathy in cryptogenic stroke patients: Implications for personalized clinical management

    European Stroke Journal

  3. Plasma small extracellular vesicles: Markers and mediators of atrial scar, in patients with atrial fibrillation

    Heart Rhythm, Vol. 22, Núm. 12, pp. 3257-3267

  4. Semaglutide Modulates Proinflammatory Epicardial Adipogenesis With Paracrine Effects on hiPSC-Atrial Cardiomyocytes

    JACC: Basic to Translational Science, Vol. 10, Núm. 9

2024

  1. Carbohydrate antigen 125 on epicardial fat and its association with local inflammation and fibrosis-related markers

    Journal of Translational Medicine, Vol. 22, Núm. 1

  2. Combined Sodium-Glucose-Transporters Inhibitors and Glucagon-Like-Peptide Receptor Agonist Compared With Monotherapy Improves Long-Term Survival: A Real-World Registry

    American Journal of Medicine, Vol. 137, Núm. 8, pp. 761-769.e1

  3. Endocrine activity of dysfunctional adipose tissue: Cardiovascular risk and progression markers

    International Journal of Cardiology

  4. Enhanced Levels of Adiposity, Stretch and Fibrosis Markers in Patients with Coexistent Heart Failure and Atrial Fibrillation

    Journal of Cardiovascular Translational Research, Vol. 17, Núm. 1, pp. 13-23

  5. FABP4 Enhances Lipidic and Fibrotic Cardiac Structural and Ca2+ Dynamic Changes

    Circulation: Arrhythmia and Electrophysiology, Vol. 17, Núm. 9, pp. e012683

  6. Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network

    Cardiovascular Diabetology, Vol. 23, Núm. 1

2023

  1. Clinical Profiling and Biomarkers for Post-Operative Atrial Fibrillation Prediction in Patients Undergoing Cardiac Surgery

    Journal of Clinical Medicine, Vol. 12, Núm. 10

  2. Effect of dapagliflozin on COVID-19 infection and risk of hospitalization

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 9, pp. 2335-2342

  3. Role of Soluble ST2 Biomarker in Predicting Recurrence of Atrial Fibrillation after Electrical Cardioversion or Pulmonary Vein Isolation

    International Journal of Molecular Sciences, Vol. 24, Núm. 18

2022

  1. Diabesity in Elderly Cardiovascular Disease Patients: Mechanisms and Regulators

    International journal of molecular sciences, Vol. 23, Núm. 14

  2. Relaxin-2 plasma levels in atrial fibrillation are linked to inflammation and oxidative stress markers

    Scientific Reports, Vol. 12, Núm. 1

  3. Synergism between obesity and HFpEF on neutrophils phenotype and its regulation by adipose tissue-molecules and SGLT2i dapagliflozin

    Journal of Cellular and Molecular Medicine, Vol. 26, Núm. 16, pp. 4416-4427

  4. The Effect of Mineralocorticoid Receptor 3 Antagonists on Anti-Inflammatory and Anti-Fatty Acid Transport Profile in Patients with Heart Failure

    Cells, Vol. 11, Núm. 8

  5. The Role of Fatty Acid-Binding Protein 4 in the Characterization of Atrial Fibrillation and the Prediction of Outcomes after Catheter Ablation

    International Journal of Molecular Sciences, Vol. 23, Núm. 19